DOCSLIB.ORG

Antimicrobial Agents and Chemotherapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antimicrobial Agents and Chemotherapy ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Voliume 22 Contents for November 1982 No. 5 Mechanisms of Action: Physiological Effects Mechanism of Action of Dnacin B1, a New Benzoquinoid Antibiotic with Antitumor Properties. SEIICHI TANIDA,* TORU HASEGAWA, AND MASAHIKO YONEDA .... .................. 7735-742 Synergism Between Aminoglycosides and Cephalosporins with An- tipseudomonal Activity: Interaction Index and Killing Curve Method. HANS 0. HALLANDER,* KATHRINE DORNBUSCH, LENA GEZELIUS, KARIN JACOBSON, AND INGA KARLSSON .... 7743-752 Diffusion of j-Lactam Antibiotics Through Liposome Membranes Containing Purified Porins. YORIKo KOBAYASHI, IKUKO TAKAHASHI, AND TALJI NAKAE* ..... ...................... 7775-780 Influence of Subinhibitory Concentrations of Penicillin, Cephalothin, and Clindamycin on Staphylococcus aureus Growth in Human Phagocytic Cells. GREG R. ELLIOTT,* PHILLIP K. PETERSON, HENRI A. VERBRUGH, MARK R. FREIBERG, JQHN R. HOIDAL, AND PAUL G. QUIE ....................................... 781-784 Antibacterial Action of Gramicidin S and Tyrocidines in Relation to Active Transport, In Vitro Transcription, and Spore Out- growth. W. DANDERS, M. A. MARAHIEL,* M. KRAUSE, N. Kosui, T. KATO, N. IZUMIYA, AND H. KLEINKAUF ... ...... 7785-790 Transport of the Lipophilic Analog Minocycline Differs from That of Tetracycline in Susceptible and Resistant Escherichia coli Strains. LAURA M. MCMURRY,* JOANNE C. CULLINANE, AND STUART B. LEVY ......... ............................... 7791-799 Effect of 2-Alkynoic Acids on In Vitro Growth of Bacterial and Mammalian Cells. WATTANA KONTHIKAMEE, JOHN R. GILBERTSON,* HERMAN LANGKAMP, AND HERMAN GERSHON 8305-809 7-Hydroxytropolone: an Inhibitor of Aminoglycoside-2"-O-Adenylyl- transferase. N. E. ALLEN,* W. E. ALBORN, JR., J. N. HOBBS, JR., AND H. A. KIRST ....... ............................. 8324-831 Mechanisms of Resistance Candida albicans Resistance to 5-Fluorocytosine: Frequency of Partially Resistant Strains Among Clinical Isolates. KEITH S. DEFEVER, WILLIAM L. WHELAN, ALVIN L. ROGERS, EVERETT S. BENEKE, JAMES M. VESELENAK, AND DAVID R. SOLL* .... 8310-815 Selection for Mercurial Resistance in Hospital Settings. FORBES D. PORTER, SIMON SILVER,* CATHERINE ONG, AND HIDEOMI NAKAHARA .............................................. B52-858 Monitoring of Plasmid-Encoded, Trimethoprim-Resistant Dihydrofo- late Reductase Genes: Detection of a New Resistant En- zyme. MARY E. FLING, LESLIE WALTON, AND LYNN P. ELWELL* ................................................ B82-888 Nonenzymatic Chloramphenicol Resistance Determinants Specified by Plasmids R26 and R55-1 in Escherichia coli K-12 Do Not Confer High-Level Resistance to Fluorinated Analogs. C. J. DORMAN AND T. J. FOSTER* .................... S912-914 Continued on following page Continued from preceding page Susceptibility Interactions Among Amphotericin B, 5-Fluorocytosine, Ketocona- zole, and Miconazole Against Pathogenic Fungi In Vitro. F. C. ODDS ................................................... 763-770 Bacteroides fragilis Resistance to Clindamycin In Vitro. ANIBAL SOSA, FRANCIS P. TALLY,* NILDA V. JACOBUS, AND SHERWOOD L. GORBACH ................ ............................ 771-774 In Vitro Activity of Azthreonam, a Monobactam Antibiotic. NILDA V. JACOBUS, MARIA C. FERREIRA, AND MICHAEL BARZA* .... 832-838 Effect of Calcium, Magnesium, and Zinc on Ticarcillin and Tobramy- cin Alone and in Combination Against Pseudomonas aerugino- sa. JEFFREY J. ZURAVLEFF, VICTOR L. Yu,* ROBERT B. YEE, M. K. ZAPHYR, WARREN DIVEN, AND FLOYD B. TAYLOR .... 839-843 Cefotetan, a New Cephamycin: Comparison of In Vitro Antimicrobi- al Activity with Other Cephems, P-Lactamase Stability, and Preliminary Recommendations for Disk Diffusion Test- ing. LEONA W. AYERS,* RONALD N. JONES, ARTHUR L. BAR- RY, CLYDE THORNSBERRY, PETER C. FUCHS, THOMAS L. GA- VAN, E. HUGH GERLACH, AND HERBERT M. SOMMERS ....... 859-877 Susceptibility of Bacteroides spp. to Heavy Metals. THOMAS V. RILEY* AND BRIAN J. MEE ....... ........................ 889-892 Activity of Pirlimycin (U57930E) Against Strains of the Bacteroides fragilis Group. J. A. GARCIA-RODRIGUEZ,* J. E. GARCIA-SAN- CHEZ, J. PRIETO, AND A. SANCHEZ DE S. LORENZO .... ..... 893-894 Susceptibility of Clinical Isolates of Staphylococcus saprophyticus to Fifteen Commonly Used Antimicrobial Agents. L. E. NI- COLLE* AND G. K. M. HARDING ...... .................... 895-896 Susceptibility of Group B Streptococci to 16 P-Lactam Antibiotics, Including New Penicillin and Cephalosporin Deriva- tives. MICHAEL R. JACOBS,* FRANCES KELLY, AND WILLIAM T. SPECK ............................................... 897-900 Synergism Between Vancomycin and Gentamicin or Tobramycin for Methicillin-Susceptible and Methicillin-Resistant Staphylococ- cus aureus Strains. CHATRCHAI WATANAKUNAKORN* AND JOANN C. TISONE ........... ............................ 903-905 In Vitro Susceptibility of Methicillin-Resistant and Methicillin-Sus- ceptible Staphylococcus aureus Strains to N-Formimidoyl Thienamycin. JOYCE L. WITTE, FRANCISCO L. SAPICO,* AND HANNA N. CANAWATI ......... .......................... 906-908 Effects of a Vancomycin-Rifampin Combination on Enterococ- Ci. CHATRCHAI WATANAKUNAKORN* AND JOANN C. TISONE 915-916 Antagonism Between Nafciilin or Oxacillin and Rifampin Against Staphylococcus aureus. CHATRCHAI WATANAKUNAKORN* AND JOANN C. TISONE .......... ......................... 920-922 Susceptibility of Haemophilus influenzae Type b to Cefaclor and Influence of Inoculum Size. ROBERT M. LEVIN,* PARVIN H. AZIMI, AND MARY G. DUNPHY ....... ..................... 923-925 Susceptibility of Neisseria meningitidis and Neisseria gonorrhoeae Isolates to N-Formimidoyl Thienamycin. EDWARD J. DUDEK, JANE D. STEPHENSON, MARJORIE BOHNHOFF, AND STEPHEN A. LERNER* ................................................ 926-929 Activity of Nine Antimicrobial Agents Against Lancefield Group C and Group G Streptococci. KENNETH V. I. ROLSTON, JACK L. LEFROCK,* AND RONALD F. SCHELL ...... ................ 930-932 Continued on following page Continued from preceding page Analytical Procedures Assay of Amoxicillin and Clavulanic Acid, the Components of Augmentin, in Biological Fluids with High-Performance Liquid Chromatography. MARK FOULSTONE AND CHRISTOPHER READING* ............................................... 753-762 High-Pressure Liquid Chromatographic Method for Determination of Sch 29482 in Human Serum. H. KIM, E. ODEN, AND C. LIN* 848-851 Evaluation of the Cathra Inoculating Device for Susceptibility Test- ing of Methicillin-Susceptible and Methicillin-Resistant Staphy- lococcus aureus Strains. JOHN M. BOYCE,* MARY C. BONNER, AND W. R. LOCKWOOD ........... ........................ 901-902 Experimental Therapeutics Antibacterial Activities of SM-1652 Compared with Those of Other Broad-Spectrum Cephalosporins. MASUHIRO KATO,* MATSUHISA INOUE, AND SUSUMU MITSUHASHI .... ......... 721-727 In Vitro and In Vivo Antibacterial Activity of T-1982, a New Semisynthetic Cephamycin Antibiotic. M. TAI, Y. FUKUOKA, A. YOTSUJI, K. KUMANO, M. TAKAHATA, H. MIKAMI, T. YASUDA,* I. SAIKAWA, AND S. MITSUHASHI ..... ........... 728-734 Activity of Ketoconazole and Its Deacyl Derivative Against Plasmo- diumfalciparum and Candida Isolates. MICHAEL A. PFALLER, JOSEPH J. SEGAL, AND DONALD J. KROGSTAD* .... ......... 917-919 Pharmacology Two-Compartment Comparison of Gentamicin and Tobramycin in Normal Volunteers. MARTIN ADELMAN, EVAN EVANS, AND JEROME J. SCHENTAG* ........... ........................ 800-804 Pharmacokinetic Characteristics of Intravenous Ceftriaxone in Nor- mal Adults. ALAN A. POLLOCK,* PATRICIA E. TEE, IN- DRAVADAN H. PATEL, JONATHAN SPICEHANDLER, MICHAEL S. SIMBERKOFF, AND JAMES R. RAHAL, JR. ................... 816-823 Role of Serum Protein Binding and Multiple Antibiotic Doses in the Extravascular Distribution of Ceftizoxime and Cefotax- ime. DALE N. GERDING,* LINDA L. VAN ETTA, AND LANCE R. PETERSON ............................................ 844-847 Pharmacokinetics, Protein Binding, and Extravascular Distribution of Ceftizoxime in Normal Subjects. LANCE R. PETERSON,* DALE N. GERDING, LINDA L. VAN ETTA, JOHN H. ECKFELDT, AND TOM N. LARSON ........... ......................... 878-881 Comparative Penetration of Azlocillin and Mezlocillin into Cerebro- spinal Fluid of Normal Rabbits and Rabbits with Experimentally Induced Pseudomonas aeruginosa Meningitis. GLENN R. HODGES* AND SAMUEL E. WORLEY ...... ................. 909-911 Erratum Activity of Cefoperazone Against Ampicillin-Resistant Bacteria in Agar and Broth Dilution Tests. FRITZ H. KAYSER, GIOVANNA MORENZONI, AND FRANSOISE HOMBERGER ..... ............ 933 * Asterisk refers to person to whom inquiries regarding the paper should be addressed..
Load more

Recommended publications
  • In Vitro and in Vivo Study of Fosfomycin in Methicillin-Resistant Staphylococcus Aureus Septicaemia
    J. Ilyg., Camb. (1980), 96, 419-423 419 Printed in Great Britain In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia BY W. Y. LAU, C. H. TEOH-CHAN,* S. T. FAN AND K. F. LAU* Government Surgical Unit, Queen Mary Hospital, and * Department of Microbiology, University of Hong Kong {Received 15 October 19S5; accepted 12 December 19S5) SUMMARY Five hundred strains of methicillin-resistant Staphylococcus aureus were tested against various anti-staphylococcal agents. Vancomycin, fusidic acid and fosfo- mycin were found to be the most effective. Only 1 strain out of 500 was resistant to fosfomycin. Three patients with methicillin-resistant Staphylococcus aureus septicaemia were successfully treated by fosfomycin. We conclude that fosfomycin could be the drug of choice for methicillin-resistant Staphylococcns aureus infection. INTRODUCTION Outbreaks of methicillin-resistant Staphylococcus aureus (MRSA) infection are causing increasing problems in centres all over the world (Thompson & Wenzel, 1982; Editorial, 1983). There has been a gradual increase in the incidence of MRSA in our hospital in Hong Kong from 317 in 1982 (18-7% of all S. aureus isolated) to 511 in 1983 (32-7%) and 833 in 1984 (34-9%). In vitro, resistance of MRSA is often demonstrated to many anti-staphylococcal agents including the penicillins, first-generation cephalosporins, aminoglycosides, erythromycin, clindamycin and chloramphenicol (Peacock et al. 1981). Second- and third-generation cephalosporins also have poor activity in vitro (Thompson, Fisher & Wenzel, 1982) though many MRSA strains have been found to be susceptible to rifampicin, trimethoprim- sulphamethoxazole and fusidic acid (Watanakunakorn, 1983). However, clinical experience of treating serious staphylococeal infection with rifampicin and trimethoprim-siilphamethoxazole is limited (Guenther & Wenzel, 1984) and fully resistant organisms may emerge rapidly after exposure to fusidic acid in vitro and in vivo (Watanakunakorn, 1983).
    [Show full text]
  • Thienamycin (Imipenem)
    1520 THE JOURNAL OF ANTIBIOTICS OCT. 1989 CONVERSION OF OA-6129 B2 INTO OA-6129 B2, a fermentation carbapenem product, (5i?,6^)-6-[(i?)- l -FLUOROETHYL]-7- into optically active 88617, an 8-fluorinated OXO- 3 -[(7V,Ar,Ar-TRIM ETHYL- carbapenem derivative which improved antimicro- CARBAMIMIDOYL)METHYL]THIO- bial activity and dehydropeptidase-I stability. l -AZABICYCLO[3.2.0]HEPT-2-ENE- Treatment of OA-6129B2 sodium salt 1 with 2-CARBOXYLIC ACID (88617)t /7-nitrobenzyl (PNB) bromide or pivaloyloxymethyl chloride in DMFgave /?NB ester 2 or pivaloyl- Takeo Yoshioka, AzumaWatanabe, oxymethyl (POM) ester 3 of OA-6129 B2 (Fig. 1). Noritaka Chida and Yasuo Fukagawa The two hydroxyl groups in the pantoyl moiety of OA-6129B2 were protected by isopropylidena- Central Research Laboratories, tion for differentiation from the C-8 hydroxyl Sanraku Incorporated, 4-9-1 Johnan, Fujisawa 251, Japan group. The protected compound4 or 5 was allowed to (Received for publication May 25, 1989) react with 1.2 equiv of diethylaminosulfur trifluoride (DAST)11} at -68°C in methylene chloride for 10 minutes. After the reaction mixture was diluted with Since the epoch-making discovery of thienamy- methylene chloride and washed with a saturated cin2), a numberof extensive studies have been carried aqueous sodium bicarbonate solution, silica gel out on the development of clinically useful car- column chromatography of the organic layer pro- bapenem compounds. As a result, formimidoyl- vided the desired fluorinated compound 6 or 7 thienamycin (imipenem) has recently been put on having a fluorine atom in the R configuration at C-8 the market as a combination drug (Primaxin)3) in 43 or 49% yield, respectively.
    [Show full text]
  • Profile Profile Profile Uses and Administration
    Gramicidin/lmipenem 309 Graneodin N; Graneodin; Gripaben Caramelos; Kenacomb; t Incompatibility and stability. Intipenem is unstable at Nasomicina; Neo Coltirot; Pantometilt; Proetztotal; Tosedrin �-�P.�.�� ����---········································································· alkaline or acidic pH and the commercially available injec­ (details are given in Volume B) NF; Austral.: Kenacomb; Neosporint; Otocomb Otic; Otodex; ProprielaryPreparations tion of intipenem with cilastatin sodium for intravenous Sofradex; Soframycint; Austria: Volon A antibiotikahaltigt; V alpeda. use is buffered to provide, when reconstituted, a solution Belg. : Mycolog; Polyspectran Granticidinet; Braz.: Fonergin; Single-ingredient Preparations. UK: with pH 6.5 to 7.5. Licensed product information advises Londerm-Nt; Mud; Neolon D; Omcilon-A M; Oncibel; Oncileg; against mixing with other antibacterials. Onciplust; Canad.: Ak Spor; Antibiotic Cream; Antibiotic Plus; Complete Antibiotic Ointment; Diosporint; Neosporin; Opti­ lbafloxacin (BAN, USAN, r/NN) References. cort; Optimyxin Plus; Optimyxin; Polysporin Complete; Poly­ 1. Bigley FP, et al. Compatibility of imipenem-dlastatin sodium with Am Hosp Phann 1986; 43: 2803- sporin For Kids; Polysporin Plus Pain Relief; Polysporin Triple commonly used intravenous solutions. 9. J Antibiotic; Polysporin; Polytopic; ratio-Tria comb; Sofracort; 2. Smith GB, et al. Stability and kinetics of degradation of imipenem in Soframycin; Soframycin; Triple Antibiotic Ointment; Viaderm­ Pharm 1990; 79: 732-40. aqueous
    [Show full text]
  • Radical Sam Enzymes in Thienamycin Biosynthesis
    RADICAL SAM ENZYMES IN THIENAMYCIN BIOSYNTHESIS by Daniel Roe Marous A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland December, 2015 ©Daniel Roe Marous 2015 All rights reserved Abstract Despite its broad anti-infective activity, the biosynthesis of the paradigm carbapenem antibiotic, thienamycin, remains largely unknown. Apart from the first two biosynthetic steps shared with a simple carbapenem, the pathway sharply diverges to the more structurally complex members of this class of β-lactam antibiotics like thienamycin. Existing evidence points to three putative cobalamin-dependent, radical S- adenosylmethionine (RS) enzymes, ThnK, ThnL and ThnP, potentially being responsible for assembly of the ethyl side chain at C6, bridgehead epimerization at C5, installation of the C2-thioether side chain and C2/3-desaturation. The C2 substituent has been demonstrated to be derived from stepwise truncation of coenzyme A, but the timing of these events with respect to C2—S bond formation is not known. Using in vitro reactions with synthetically-accessed substrates, we show that ThnK of the three apparent cobalamin-dependent RS enzymes performs sequential methylations to build out the C6- ethyl side chain in a stereocontrolled manner. This enzymatic reaction produced the expected RS methylase coproducts S-adenosylhomocysteine (SAH) and 5’- deoxyadenosine (5’-dA) by LC-MS and was also found to require cobalamin. For double methylation to occur, the carbapenam substrate must bear a coenzyme A-derived C2- thioether side chain, implying the activity of a prior sulfur insertion by an unidentified enzyme. Heterologous expression of thienamycin biosynthetic enzymes in Streptomyces combined with a competition bioassay now implicates ThnL in attachment of the thioether.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • PRIMAXIN (Imipenem and Cilastatin)
    • Known hypersensitivity to any component of PRIMAXIN (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ----------------------- WARNINGS AND PRECAUTIONS ----------------------­ PRIMAXIN safely and effectively. See full prescribing information • Hypersensitivity Reactions: Serious and occasionally fatal for PRIMAXIN. hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. If an allergic reaction PRIMAXIN® (imipenem and cilastatin) for Injection, for to PRIMAXIN occurs, discontinue the drug immediately (5.1). intravenous use • Seizure Potential: Seizures and other CNS adverse reactions, such Initial U.S. Approval: 1985 as confusional states and myoclonic activity, have been reported during treatment with PRIMAXIN. If focal tremors, myoclonus, or --------------------------- RECENT MAJOR CHANGES --------------------------­ seizures occur, patients should be evaluated neurologically, placed Indications and Usage (1.9) 12/2016 on anticonvulsant therapy if not already instituted, and the dosage of Dosage and Administration (2) 12/2016 PRIMAXIN re-examined to determine whether it should be decreased or the antibacterial drug discontinued (5.2). ----------------------------INDICATIONS AND USAGE ---------------------------­ • Increased Seizure Potential Due to Interaction with Valproic Acid: PRIMAXIN for intravenous use is a combination of imipenem, a penem Co-administration of PRIMAXIN, to patients receiving valproic acid antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, or divalproex sodium results in a reduction in valproic acid indicated for the treatment of the following serious infections caused by concentrations. The valproic acid concentrations may drop below designated susceptible bacteria: the therapeutic range as a result of this interaction, therefore • Lower respiratory tract infections. (1.1) increasing the risk of breakthrough seizures. The concomitant use of • Urinary tract infections.
    [Show full text]
  • The Use of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities
    University of Montana ScholarWorks at University of Montana Graduate Student Theses, Dissertations, & Graduate School Professional Papers 2010 The seU of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities Joshua Bryant Phillips The University of Montana Let us know how access to this document benefits ouy . Follow this and additional works at: https://scholarworks.umt.edu/etd Recommended Citation Phillips, Joshua Bryant, "The sU e of Natural Product Substrates for the Synthesis of Libraries of Biologically Active, New Chemical Entities" (2010). Graduate Student Theses, Dissertations, & Professional Papers. 1100. https://scholarworks.umt.edu/etd/1100 This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES by Joshua Bryant Phillips B.S. Chemistry, Northern Arizona University, 2002 B.S. Microbiology (health pre-professional), Northern Arizona University, 2002 Presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chemistry The University of Montana June 2010 Phillips, Joshua Bryant Ph.D., June 2010 Chemistry THE USE OF NATURAL PRODUCT SUBSTRATES FOR THE SYNTHESIS OF LIBRARIES OF BIOLOGICALLY ACTIVE, NEW CHEMICAL ENTITIES Advisor: Dr. Nigel D. Priestley Chairperson: Dr. Bruce Bowler ABSTRACT Since Alexander Fleming first noted the killing of a bacterial culture by a mold, antibiotics have revolutionized medicine, being able to treat, and often cure life-threatening illnesses and making surgical procedures possible by eliminating the possibility of opportunistic infection.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • Drug Delivery System Utilizing Thermosetting Gels
    Europaisches Patentamt European Patent Office 5) Publication number: 3 126 684 Bl Dffice europeen des brevets © EUROPEAN PATENT SPECIFICATION S Date of publication of patent specification: 28.08.91 (£) Int. CI.5: A61 K 47/00, A61K9/06 © Application number: 84400982.9 g) Date of filing: 15.05.84 © Drug delivery system utilizing thermosetting gels. (is) Priority: 16.05.83 US 495238 @ Proprietor: MERCK & CO. INC. 16.05.83 US 495239 126, East Lincoln Avenue P.O. Box 2000 16.05.83 US 495240 Rahway New Jersey 07065-0900(US) 16.05.83 US 495321 @ Inventor: Haslam, John L. @ Date of publication of application: RFD 2, Box 259-B 28.11.84 Bulletin 84/48 Lawrence Kansas 66044(US) Inventor: Higuchi, Takeru © Publication of the grant of the patent: 2811 Schwarz Road 28.08.91 Bulletin 91/35 Lawrence, Kansas 66044(US) Inventor: Mlodozeniec, Arthur R. @ Designated Contracting States: 1704 St. Andrews Drive AT BE CH DE FR GB IT LI LU NL SE Lawrence Kansas 66044(US) @ References cited: AU-A- 482 821 0 Representative: Ahner, Francis et al CA-A- 1 072 413 CABINET REGIMBEAU, 26, avenue Kleber FR-A- 1 598 998 F-75116 Paris(FR) N.F.ESTRIN et al.: "CTFA COSMETIC INGRE- DIENT DICTIONARY", Third Edition, The Cos- metic, Toiletry and Fragrance Association, Inc., Washington, D.C., US; CD 00 CO CO O Note: Within nine months from the publication of the mention of the grant of the European patent, any person - may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Author Section
    AUTHOR SECTION patients with new onset of fever, demographic, clinical, and laborato- Mycoplasma spp. Overall, the spectrum of antibacterial activity indi- ry variables were obtained during the 2 days after inclusion, while cates a potential role for this combination in the treatment of diffi- microbiological results for a follow-up period of 7 days were collect- cult-to-treat Gram-positive infections, including those caused by ed. Patients were followed up for survival or death, up to a maximum multidrug-resistant organisms. Since this activity extends to Gram- of 28 days after inclusion. MEASUREMENTS AND RESULTS: Of negative respiratory bacteria, quinupristin/dalfopristin may also find all patients, 95% had SIRS, 44% had sepsis with a microbiologically a role in the treatment of atypical, as well as typical, pneumonia. confirmed infection, and 9% died. A model with a set of variables all significantly (p<0.01) contributing to the prediction of mortality was Boubaker A. et al. [Investigation of the urinary tract in children in nuclear med- derived.The set included the presence of hospital-acquired fever, the icine]. Rev Med Suisse Romande. 2000; 120(3) : 251-7.p Abstract: peak respiratory rate, the nadir score on the Glasgow coma scale, and The early detection of urologic abnormalities by antenatal sonogra- the nadir albumin plasma level within the first 2 days after inclusion. phy has resulted in the investigation of many infants and neonates for This set of variables predicted mortality for febrile patients with suspicion of either obstructive uropathy or reflux nephropathy. microbiologically confirmed infection even better.The predictive val- Nuclear medicine techniques allow to assess renal parenchyma ues for mortality of SIRS and sepsis were less than that of our set of integrity, to detect pyelonephritic scars and to measure absolute and variables.
    [Show full text]
  • Individualization of Drug Therapy Considering Pharmacokinetic and Clinical Factors
    Individualization of drug therapy considering pharmacokinetic and clinical factors Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Martin Reinhold Munz aus Gaildorf Würzburg 2018 Eingereicht bei der Fakultät für Chemie und Pharmazie am Gutachter der schriftlichen Arbeit 1. Gutachter: Prof. Dr. Fritz Sörgel 2. Gutachter: Prof. Dr. Ulrike Holzgrabe Prüfer des öffentlichen Promotionskolloquiums 1. Prüfer: 2. Prüfer: 3. Prüfer: Datum des öffentlichen Promotionskolloquiums Doktorurkunde ausgehändigt am Die vorliegende Arbeit wurde am IBMP - Institut für Biomedizinische und Pharmazeutische Forschung in Nürnberg-Heroldsberg angefertigt. This thesis has been accomplished at the IBMP - Institute for Biomedical and Pharmaceutical Research in Nürnberg-Heroldsberg. Für meine Familie III IV Acknowledgement This thesis has been accomplished under the supervision of Professor Dr. Fritz Sörgel, IBMP - Institute for Biomedical and Pharmaceutical Research in Nürnberg- Heroldsberg, and Professor Dr. Ulrike Holzgrabe, Department of Pharmaceutical Chemistry, University of Würzburg, Germany. First and foremost, I greatly thank Professor Dr. Sörgel for the assignment of the scientific topic for this Ph.D. thesis, for his continuous support, advice and guidance during this thesis and for the opportunity of working on fascinating clinical projects in collaboration with the Department of Hematology and Oncology and the Department of Anesthesiology and Intensive Care Medicine of the Paracelsus Medical University, Nürnberg, Germany, and the Department for Trauma Surgery, University of Erlangen, Germany. My warmest thank you goes to Professor Dr. Ulrike Holzgrabe for supporting this Ph.D. thesis, providing feedback and guiding together with Professor Dr. Sörgel the direction and progress of this work. My warmest thank you also goes to Professor Dr.
    [Show full text]
  • Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing In
    Original Research Title: Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy Authors: Susan J. Lewis, Pharm.D, BCPS Department of Clinical Pharmacy University of Michigan College of Pharmacy Michael B. Kays, Pharm.D, FCCP Department of Pharmacy Practice Purdue University College of Pharmacy Corresponding author: Bruce A. Mueller, Pharm.D, FCCP, FASN, FNKF Department of Clinical Pharmacy University of Michigan College of Pharmacy 428 Church Street Ann Arbor, Michigan 48109 Phone 734-615-4578 Fax 734-763-4480 [email protected] This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jcph.727. This article is protected by copyright. All rights reserved. Declaration of Conflicting Interests Drs. Mueller and Lewis have received grant funding from NxStage Medical, Inc., and Merck. Dr. Mueller has served on NxStage Medical Inc’s speaker’s bureau. Dr. Kays has nothing to disclose. Portions of this paper were presented as a poster presentation at American Society of Nephrology (ASN) Annual Meeting 2015, San Diego, CA on November 7, 2015. Funding This study was funded by NxStage Medical, Inc. Word Count for the body: 3949 Words Tables: 5 Figure: 1 References: 70 Abstract This article is protected by copyright. All rights reserved. 2 Pharmacokinetic/pharmacodynamic analyses with Monte Carlo Simulations (MCS) can be used to integrate prior information on model parameters to a new renal replacement therapy (RRT) to develop optimal drug dosing when pharmacokinetic trials are not feasible.
    [Show full text]